Back to search results

Optimizing Mango Consumption for Prediabetes

This study is looking at how eating mangoes affects blood sugar and inflammation in people with prediabetes. Researchers want to find out the best time to eat mangoes relative to meals to help manage blood sugar. You might be able to join if you are between 20 and 60 years old, have a Body Mass Index (BMI) between 25-35 (a measure of body fat), and have fasting blood sugar levels that indicate prediabetes (100-125 mg/dL or HbA1c between 5.7-6.4%). The study will compare a mango beverage to an Italian Ice beverage. Success would mean seeing positive changes in your blood sugar and insulin levels after eating mangoes. The current status of this study is unclear.

Study design
This is an interventional study, meaning participants will receive specific interventions (mango or control beverage). It plans to enroll 30 participants.
What's involved
Participation lasts about five weeks, with one screening visit (1 hour) and four study-day visits (each 8 hours). You will need to fast before some visits, and blood and urine samples will be collected.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints for this study are measured at 7 hours after intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06986161

Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals

Active, Not Recruiting
NAAges 20–60InterventionalPrevention
Clinical Nutrition Research Center, Illinois Institute of Technology
~33 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:MangoControl Beverage

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in postprandial glucose
Measured over 7 hours
+5 more outcomes measured

Conditions

Pre Diabetes

Explore related trials

Diabetes type

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Indika Edirisinghe, PhD. · PRINCIPAL_INVESTIGATOR · Illinois Institute of Technology
  • Britt Burton-Freeman, PhD. · PRINCIPAL_INVESTIGATOR · Illinois Institute of Technology

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Be between 20-60 years old.
Have a BMI of 25-35 kilograms per square meter.
Have fasting blood glucose between 100-125 milligrams per deciliter or Glycated hemoglobin (HbA1c) between 5.7-6.4%.
Be non-smokers for at least 12 months.
Be generally healthy, with no major organ-related diseases.
Not take medications or supplements that could interfere with the study.
Be able to follow study procedures, including dietary restrictions and scheduled visits.

Exclusion

Smoke, vape, or use marijuana.
Have allergies or intolerance to mangoes or study foods.
Have blood pressure above 160/100 millimeters of Mercury.
Have fasting blood glucose above 125 milligrams per deciliter.
Have a history of major heart disease, stroke, or cancer in the past five years.
Be pregnant, planning to become pregnant, or breastfeeding.
Take anti-inflammatory drugs or certain dietary supplements.
Have had major surgery or trauma in the past two months.
Follow extreme diets (e.g., vegan, Atkins).
Have used antibiotics in the last six weeks.
Have a history of eating disorders or substance abuse in the past two years.
Drink more than three cups of coffee or tea per day.
Have donated blood in the last three months.
Be professional athletes or do excessive exercise.
Have had weight changes of more than 11 pounds in the past two months.
Work overnight shifts.

What this trial measures

  • Change in postprandial glucose7 hours

    Change in postprandial glucose as measured by absolute values and calculated insulin sensitivity using homeostasis model assessment of fasting insulin sensitivity (HOMA-%S) and B-cell function (HOMA-%).

  • Change in postprandial glucose through peripheral insulin sensitivity7 hours

    Change in postprandial glucose as measured by assessment of peripheral insulin sensitivity using Matsuda index.

  • Change in postprandial insulin7 hours

    Change in postprandial insulin as measured by absolute values and calculated insulin sensitivity using homeostasis model assessment of fasting insulin sensitivity (HOMA-%S) and B-cell function (HOMA-%).

  • Change in postprandial insulin through peripheral insulin sensitivity7 hours

    Change in postprandial insulin as measured by assessment of peripheral insulin sensitivity using Matsuda index.

  • Evaluate Interleukin-6 (IL-6) as an index of systemic inflammatory response7 hours

    Assessments to address this aim will include analysis of systemic markers of inflammation (IL-6) in plasma using ELISA method

  • Evaluate Tumor Necrosis Factor-alpha (TNF-α) as an index of systemic inflammatory response7 hours

    Assessments to address this aim will include analysis of systemic markers of inflammation (TNF-α) in plasma using ELISA method